Cargando…
Breakthrough Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation
Despite the recent introduction of mold-active antifungal prophylaxis (MAP), breakthrough invasive fungal infections (b-IFI) still represent a possible complication and a cause of morbidity and mortality in hematological patients and allogeneic hematopoietic stem-cell transplantation recipients (HSC...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146885/ https://www.ncbi.nlm.nih.gov/pubmed/33925188 http://dx.doi.org/10.3390/jof7050347 |
_version_ | 1783697500844064768 |
---|---|
author | Liberatore, Carmine Farina, Francesca Greco, Raffaella Giglio, Fabio Clerici, Daniela Oltolini, Chiara Lupo Stanghellini, Maria Teresa Barzaghi, Federica Vezzulli, Paolo Orsenigo, Elena Corti, Consuelo Ciceri, Fabio Peccatori, Jacopo |
author_facet | Liberatore, Carmine Farina, Francesca Greco, Raffaella Giglio, Fabio Clerici, Daniela Oltolini, Chiara Lupo Stanghellini, Maria Teresa Barzaghi, Federica Vezzulli, Paolo Orsenigo, Elena Corti, Consuelo Ciceri, Fabio Peccatori, Jacopo |
author_sort | Liberatore, Carmine |
collection | PubMed |
description | Despite the recent introduction of mold-active antifungal prophylaxis (MAP), breakthrough invasive fungal infections (b-IFI) still represent a possible complication and a cause of morbidity and mortality in hematological patients and allogeneic hematopoietic stem-cell transplantation recipients (HSCT). Data on incidence and type of b-IFI are limited, although they are mainly caused by non-fumigatus Aspergillus and non-Aspergillus molds and seem to depend on specific antifungal prophylaxis and patients’ characteristics. Herein, we described the clinical presentation and management of two cases of rare b-IFI which recently occurred at our institution in patients undergoing HSCT and receiving MAP. The management of b-IFI is challenging due to the lack of data from prospective trials and high mortality rates. A thorough analysis of risk factors, ongoing antifungal prophylaxis, predisposing conditions and local epidemiology should drive the choice of antifungal treatments. Early broad-spectrum preemptive therapy with a lipid formulation of amphotericin-B, in combination with a different mold-active azole plus/minus terbinafine, is advisable. The therapy would cover against rare azole-susceptible and -resistant fungal strains, as well as atypical sites of infections. An aggressive diagnostic work-up is recommended for species identification and subsequent targeted therapy. |
format | Online Article Text |
id | pubmed-8146885 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81468852021-05-26 Breakthrough Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation Liberatore, Carmine Farina, Francesca Greco, Raffaella Giglio, Fabio Clerici, Daniela Oltolini, Chiara Lupo Stanghellini, Maria Teresa Barzaghi, Federica Vezzulli, Paolo Orsenigo, Elena Corti, Consuelo Ciceri, Fabio Peccatori, Jacopo J Fungi (Basel) Case Report Despite the recent introduction of mold-active antifungal prophylaxis (MAP), breakthrough invasive fungal infections (b-IFI) still represent a possible complication and a cause of morbidity and mortality in hematological patients and allogeneic hematopoietic stem-cell transplantation recipients (HSCT). Data on incidence and type of b-IFI are limited, although they are mainly caused by non-fumigatus Aspergillus and non-Aspergillus molds and seem to depend on specific antifungal prophylaxis and patients’ characteristics. Herein, we described the clinical presentation and management of two cases of rare b-IFI which recently occurred at our institution in patients undergoing HSCT and receiving MAP. The management of b-IFI is challenging due to the lack of data from prospective trials and high mortality rates. A thorough analysis of risk factors, ongoing antifungal prophylaxis, predisposing conditions and local epidemiology should drive the choice of antifungal treatments. Early broad-spectrum preemptive therapy with a lipid formulation of amphotericin-B, in combination with a different mold-active azole plus/minus terbinafine, is advisable. The therapy would cover against rare azole-susceptible and -resistant fungal strains, as well as atypical sites of infections. An aggressive diagnostic work-up is recommended for species identification and subsequent targeted therapy. MDPI 2021-04-28 /pmc/articles/PMC8146885/ /pubmed/33925188 http://dx.doi.org/10.3390/jof7050347 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Liberatore, Carmine Farina, Francesca Greco, Raffaella Giglio, Fabio Clerici, Daniela Oltolini, Chiara Lupo Stanghellini, Maria Teresa Barzaghi, Federica Vezzulli, Paolo Orsenigo, Elena Corti, Consuelo Ciceri, Fabio Peccatori, Jacopo Breakthrough Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation |
title | Breakthrough Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation |
title_full | Breakthrough Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation |
title_fullStr | Breakthrough Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation |
title_full_unstemmed | Breakthrough Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation |
title_short | Breakthrough Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation |
title_sort | breakthrough invasive fungal infections in allogeneic hematopoietic stem cell transplantation |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146885/ https://www.ncbi.nlm.nih.gov/pubmed/33925188 http://dx.doi.org/10.3390/jof7050347 |
work_keys_str_mv | AT liberatorecarmine breakthroughinvasivefungalinfectionsinallogeneichematopoieticstemcelltransplantation AT farinafrancesca breakthroughinvasivefungalinfectionsinallogeneichematopoieticstemcelltransplantation AT grecoraffaella breakthroughinvasivefungalinfectionsinallogeneichematopoieticstemcelltransplantation AT gigliofabio breakthroughinvasivefungalinfectionsinallogeneichematopoieticstemcelltransplantation AT clericidaniela breakthroughinvasivefungalinfectionsinallogeneichematopoieticstemcelltransplantation AT oltolinichiara breakthroughinvasivefungalinfectionsinallogeneichematopoieticstemcelltransplantation AT lupostanghellinimariateresa breakthroughinvasivefungalinfectionsinallogeneichematopoieticstemcelltransplantation AT barzaghifederica breakthroughinvasivefungalinfectionsinallogeneichematopoieticstemcelltransplantation AT vezzullipaolo breakthroughinvasivefungalinfectionsinallogeneichematopoieticstemcelltransplantation AT orsenigoelena breakthroughinvasivefungalinfectionsinallogeneichematopoieticstemcelltransplantation AT corticonsuelo breakthroughinvasivefungalinfectionsinallogeneichematopoieticstemcelltransplantation AT cicerifabio breakthroughinvasivefungalinfectionsinallogeneichematopoieticstemcelltransplantation AT peccatorijacopo breakthroughinvasivefungalinfectionsinallogeneichematopoieticstemcelltransplantation |